ES2759936T3 - Proteínas de unión a albúmina sérica - Google Patents
Proteínas de unión a albúmina sérica Download PDFInfo
- Publication number
- ES2759936T3 ES2759936T3 ES12727658T ES12727658T ES2759936T3 ES 2759936 T3 ES2759936 T3 ES 2759936T3 ES 12727658 T ES12727658 T ES 12727658T ES 12727658 T ES12727658 T ES 12727658T ES 2759936 T3 ES2759936 T3 ES 2759936T3
- Authority
- ES
- Spain
- Prior art keywords
- alb
- amino acid
- seq
- polypeptide
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000007562 Serum Albumin Human genes 0.000 title description 13
- 108010071390 Serum Albumin Proteins 0.000 title description 13
- 102000014914 Carrier Proteins Human genes 0.000 title description 2
- 108091008324 binding proteins Proteins 0.000 title description 2
- 229920001184 polypeptide Polymers 0.000 claims abstract description 74
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 74
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 74
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 62
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 52
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 52
- 150000001875 compounds Chemical class 0.000 claims abstract description 18
- 150000001413 amino acids Chemical class 0.000 claims abstract description 12
- 102000008100 Human Serum Albumin Human genes 0.000 claims abstract description 10
- 108091006905 Human Serum Albumin Proteins 0.000 claims abstract description 10
- 239000000126 substance Substances 0.000 claims abstract description 8
- 150000005829 chemical entities Chemical class 0.000 claims abstract description 7
- 125000006850 spacer group Chemical group 0.000 claims abstract description 6
- 230000001225 therapeutic effect Effects 0.000 claims description 54
- 108060003951 Immunoglobulin Proteins 0.000 claims description 30
- 102000018358 immunoglobulin Human genes 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 150000007523 nucleic acids Chemical group 0.000 claims description 7
- 239000002773 nucleotide Substances 0.000 claims description 5
- 125000003729 nucleotide group Chemical group 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 3
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 53
- 235000018102 proteins Nutrition 0.000 description 33
- 230000014509 gene expression Effects 0.000 description 30
- 102000037865 fusion proteins Human genes 0.000 description 26
- 108020001507 fusion proteins Proteins 0.000 description 26
- 101000616562 Danio rerio Sonic hedgehog protein A Proteins 0.000 description 19
- 101000616493 Xenopus laevis Sonic hedgehog protein Proteins 0.000 description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 16
- 238000000855 fermentation Methods 0.000 description 14
- 230000004151 fermentation Effects 0.000 description 14
- 201000010099 disease Diseases 0.000 description 13
- 238000003860 storage Methods 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 101000693967 Trachemys scripta 67 kDa serum albumin Proteins 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 102000009027 Albumins Human genes 0.000 description 8
- 108010088751 Albumins Proteins 0.000 description 8
- 241000235058 Komagataella pastoris Species 0.000 description 8
- 230000002265 prevention Effects 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 241000235648 Pichia Species 0.000 description 7
- 208000037765 diseases and disorders Diseases 0.000 description 7
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 238000011269 treatment regimen Methods 0.000 description 7
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 102220597331 Coiled-coil domain-containing protein 144A_Q108L_mutation Human genes 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 239000002028 Biomass Substances 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 102220570985 Uncharacterized protein C7orf57_A74S_mutation Human genes 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000004007 reversed phase HPLC Methods 0.000 description 3
- 102220093685 rs374006397 Human genes 0.000 description 3
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 101100203200 Danio rerio shha gene Proteins 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 241000282567 Macaca fascicularis Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102000004473 OX40 Ligand Human genes 0.000 description 2
- 108010042215 OX40 Ligand Proteins 0.000 description 2
- 241000235070 Saccharomyces Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 102200071074 rs34712643 Human genes 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- 101150058750 ALB gene Proteins 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000008102 Ankyrins Human genes 0.000 description 1
- 108010049777 Ankyrins Proteins 0.000 description 1
- -1 CTLA- 4 Proteins 0.000 description 1
- 102220612213 Calcyclin-binding protein_E1D_mutation Human genes 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101001056707 Homo sapiens Proepiregulin Proteins 0.000 description 1
- 102000019298 Lipocalin Human genes 0.000 description 1
- 108050006654 Lipocalin Proteins 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 101100434646 Mus musculus Alb gene Proteins 0.000 description 1
- 101000930477 Mus musculus Albumin Proteins 0.000 description 1
- 102000000470 PDZ domains Human genes 0.000 description 1
- 108050008994 PDZ domains Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 102100025498 Proepiregulin Human genes 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 102220493508 Thiopurine S-methyltransferase_L49S_mutation Human genes 0.000 description 1
- 102220476045 Tubulin beta-6 chain_C50S_mutation Human genes 0.000 description 1
- 108010084455 Zeocin Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000003016 alphascreen Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000013022 formulation composition Substances 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000012933 kinetic analysis Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000002500 microbody Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000001139 pH measurement Methods 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 239000012557 regeneration buffer Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 102200058134 rs63751141 Human genes 0.000 description 1
- 102200061079 rs776498025 Human genes 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229950001790 tendamistat Drugs 0.000 description 1
- 108010037401 tendamistate Proteins 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161500464P | 2011-06-23 | 2011-06-23 | |
| PCT/EP2012/061304 WO2012175400A1 (en) | 2011-06-23 | 2012-06-14 | Serum albumin binding proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2759936T3 true ES2759936T3 (es) | 2020-05-12 |
Family
ID=46298413
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12727658T Active ES2759936T3 (es) | 2011-06-23 | 2012-06-14 | Proteínas de unión a albúmina sérica |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US9573992B2 (en:Method) |
| EP (3) | EP4218933A1 (en:Method) |
| JP (3) | JP6324887B2 (en:Method) |
| CN (2) | CN103619878B (en:Method) |
| AU (1) | AU2012271974B2 (en:Method) |
| CA (1) | CA2839779C (en:Method) |
| CY (1) | CY1122691T1 (en:Method) |
| DK (1) | DK2723771T3 (en:Method) |
| ES (1) | ES2759936T3 (en:Method) |
| HR (2) | HRP20192160T1 (en:Method) |
| HU (1) | HUE047238T2 (en:Method) |
| IN (1) | IN2014CN00414A (en:Method) |
| LT (1) | LT2723771T (en:Method) |
| PL (1) | PL2723771T3 (en:Method) |
| PT (1) | PT2723771T (en:Method) |
| SI (1) | SI2723771T1 (en:Method) |
| WO (1) | WO2012175400A1 (en:Method) |
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2621953B1 (en) | 2010-09-30 | 2017-04-05 | Ablynx N.V. | Biological materials related to c-met |
| US11644471B2 (en) | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| EP4218933A1 (en) * | 2011-06-23 | 2023-08-02 | Ablynx NV | Serum albumin binding proteins |
| PH12022550312A1 (en) * | 2011-06-23 | 2023-01-23 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| EP2747783B1 (en) * | 2011-09-30 | 2017-06-14 | Ablynx N.V. | Biological materials related to c-met |
| US9346884B2 (en) | 2011-09-30 | 2016-05-24 | Ablynx N.V. | Biological materials related to c-Met |
| WO2014087010A1 (en) | 2012-12-07 | 2014-06-12 | Ablynx N.V. | IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE |
| HUE056738T2 (hu) | 2014-05-16 | 2022-03-28 | Ablynx Nv | Eljárás gyógyszer elleni antitestek, különösen kezelés kapcsán kialakuló gyógyszer elleni antitestek detektálására és/vagy mérésére |
| NZ726448A (en) | 2014-05-16 | 2023-02-24 | Ablynx Nv | Improved immunoglobulin variable domains |
| NL2013661B1 (en) | 2014-10-21 | 2016-10-05 | Ablynx Nv | KV1.3 Binding immunoglobulins. |
| US11426468B2 (en) | 2014-12-19 | 2022-08-30 | Ablynx N.V. | Cysteine linked nanobody dimers |
| ES2983128T3 (es) | 2015-01-29 | 2024-10-21 | Technophage Investig E Desenvolvimento Em Biotecnologia Sa | Moléculas de anticuerpo y sistemas de administración de péptidos para su uso en la enfermedad de Alzheimer y trastornos relacionados |
| AU2016263808B2 (en) | 2015-05-21 | 2019-01-03 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
| NO2768984T3 (en:Method) | 2015-11-12 | 2018-06-09 | ||
| CN108290943A (zh) | 2015-11-13 | 2018-07-17 | 埃博灵克斯股份有限公司 | 改进的血清白蛋白结合免疫球蛋白可变结构域 |
| UA125337C2 (uk) | 2015-11-18 | 2022-02-23 | Мерк Шарп І Доум Корп. | Ctla4-зв'язувальні речовини |
| SG11201804178YA (en) | 2015-11-18 | 2018-06-28 | Merck Sharp & Dohme | Pd1 and/or lag3 binders |
| CN109071639B (zh) | 2015-11-18 | 2022-07-08 | 默沙东公司 | Pd1/ctla4结合剂 |
| WO2017085172A2 (en) | 2015-11-18 | 2017-05-26 | Ablynx Nv | Improved serum albumin binders |
| BR112018010802A2 (pt) * | 2015-11-27 | 2018-11-27 | Ablynx Nv | polipeptídeos que inibem cd40l |
| US10100106B2 (en) * | 2016-05-20 | 2018-10-16 | Harpoon Therapeutics, Inc. | Single domain serum albumin binding protein |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| EP3475699B1 (en) | 2016-06-23 | 2022-07-06 | Ablynx N.V. | Improved pharmacokinetic assays for immunoglobulin single variable domains |
| CA3043515A1 (en) | 2016-11-16 | 2018-05-24 | Ablynx Nv | T cell recruiting polypeptides capable of binding cd123 and tcr alpha/beta |
| KR102616835B1 (ko) | 2016-12-07 | 2023-12-22 | 아블린쓰 엔.브이. | 개선된 혈청 알부민 결합성 면역글로불린 단일 가변 도메인 |
| CN107674122A (zh) * | 2016-12-28 | 2018-02-09 | 天津天锐生物科技有限公司 | 一种识别人血清白蛋白的单域抗体 |
| FI3571224T3 (fi) * | 2017-01-17 | 2024-11-05 | Ablynx Nv | Parannettuja seerumialbumiinin sitojia |
| SG11201906264YA (en) | 2017-01-17 | 2019-08-27 | Ablynx Nv | Improved serum albumin binders |
| EP3589662A4 (en) | 2017-02-28 | 2020-12-30 | Harpoon Therapeutics, Inc. | INDUCTIBLE MONOVALENT ANTIGEN BINDING PROTEIN |
| WO2018178307A1 (en) | 2017-03-31 | 2018-10-04 | Ablynx N.V. | Improved immunogenicity assays |
| CN113896792B (zh) | 2017-05-12 | 2025-08-22 | 哈普恩治疗公司 | 间皮素结合蛋白质 |
| CN111630070B (zh) | 2017-10-13 | 2024-07-30 | 哈普恩治疗公司 | 三特异性蛋白质及使用方法 |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| US20200392512A1 (en) * | 2018-02-26 | 2020-12-17 | Ablynx N.V. | Nucleotide sequences encoding peptide linkers |
| WO2020061482A1 (en) | 2018-09-21 | 2020-03-26 | Harpoon Therapeutics, Inc. | Egfr binding proteins and methods of use |
| MX2021003554A (es) | 2018-09-25 | 2021-05-27 | Harpoon Therapeutics Inc | Proteinas de union a dll3 y metodos de uso. |
| CN110964107B (zh) * | 2018-09-30 | 2022-08-09 | 苏州康宁杰瑞生物科技有限公司 | Met结合分子、其组合和用途 |
| CN111138536B (zh) * | 2018-11-06 | 2021-07-09 | 瑞阳(苏州)生物科技有限公司 | 抗人血清白蛋白单域抗体的制备及其应用 |
| CN111138537B (zh) * | 2018-11-06 | 2021-07-09 | 瑞阳(苏州)生物科技有限公司 | 一种抗人血清白蛋白抗体片段、制备方法和应用 |
| SG11202111671QA (en) * | 2019-05-15 | 2021-11-29 | Crescendo Biologics Ltd | Binding molecules |
| TWI844709B (zh) | 2019-07-31 | 2024-06-11 | 美商美國禮來大藥廠 | 鬆弛素(relaxin)類似物及其使用方法 |
| BR112022010231A2 (pt) | 2019-12-06 | 2022-09-06 | Ablynx Nv | Polipeptídeos compreendendo domínios variáveis únicos de imunoglobulina direcionados a tnfalfa e ox40l |
| JP7657797B2 (ja) | 2019-12-06 | 2025-04-07 | アブリンクス エン．ヴェー． | ＴＮＦαおよびＩＬ－２３を標的化する免疫グロブリン単一可変ドメインを含むポリペプチド |
| IL293548A (en) | 2019-12-09 | 2022-08-01 | Ablynx Nv | Polypeptides comprising immunoglobulin single variable domains targeting il-13 and tslp |
| CN110988361B (zh) * | 2019-12-13 | 2020-09-18 | 山东民康生物科技有限公司 | 人血清白蛋白去除试剂盒 |
| KR20220148804A (ko) | 2020-01-08 | 2022-11-07 | 아르젠엑스 비브이 | 천포창 장애의 치료 방법 |
| CN115768463A (zh) | 2020-02-21 | 2023-03-07 | 哈普恩治疗公司 | Flt3结合蛋白及使用方法 |
| US20230136595A1 (en) | 2020-03-30 | 2023-05-04 | Ablynx Nv | Method for the production and purification of multivalent immunoglobulin single variable domains |
| EP4217390A1 (en) | 2020-09-25 | 2023-08-02 | Ablynx N.V. | Polypeptides comprising immunoglobulin single variable domains targeting il-13 and ox40l |
| CN112142846B (zh) * | 2020-10-10 | 2022-07-08 | 西北大学 | Aox特异性抗体组合及其制备方法和用途 |
| EP4237438A4 (en) * | 2020-10-27 | 2024-11-27 | Beijing QL Biopharmaceutical Co., Ltd. | GDF15 FUSION PROTEINS AND THEIR USE |
| KR20230122084A (ko) | 2020-12-18 | 2023-08-22 | 아블린쓰 엔.브이. | Tcr 알파/베타 반응성에 기초한 t 세포 동원 폴리펩타이드 |
| TW202239763A (zh) | 2020-12-18 | 2022-10-16 | 比利時商艾伯霖克斯公司 | 包含靶向ＩＬ－６和ＴＮＦ－α的免疫球蛋白單可變結構域的多肽 |
| TW202241947A (zh) | 2020-12-18 | 2022-11-01 | 比利時商艾伯霖克斯公司 | 包含靶向磷脂醯肌醇蛋白聚糖—３和ｔ細胞受體的免疫球蛋白單可變結構域的多肽 |
| KR20240034235A (ko) * | 2021-07-14 | 2024-03-13 | 베이징 큐엘 바이오파마슈티컬 컴퍼니 리미티드 | 대사 장애를 위한 융합 폴리펩타이드 |
| WO2023088295A1 (zh) * | 2021-11-17 | 2023-05-25 | 江苏先声药业有限公司 | 一种多特异性抗体及其药物用途 |
| AU2022409733A1 (en) | 2021-12-17 | 2024-08-01 | Ablynx Nv | POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TCRαβ, CD33 AND CD123 |
| WO2023134742A1 (zh) * | 2022-01-14 | 2023-07-20 | 浙江道尔生物科技有限公司 | 一种三靶点抗肿瘤药物、其制备方法及其应用 |
| AU2023290487A1 (en) | 2022-06-14 | 2025-01-30 | Ablynx Nv | Immunoglobulin single variable domains targeting t cell receptor |
| CN119698429A (zh) * | 2022-06-15 | 2025-03-25 | 阿根思有限公司 | Fcrn结合分子及使用方法 |
| MA71603A (fr) | 2022-07-27 | 2025-05-30 | Ablynx Nv | Polypeptides se liant à un épitope spécifique du récepteur fc néonatal |
| WO2024084203A1 (en) | 2022-10-18 | 2024-04-25 | Isogenica Limited | Single domain antibodies binding to albumin |
| WO2024131731A1 (zh) | 2022-12-19 | 2024-06-27 | 和铂医药(上海)有限责任公司 | "κ/λ"Fab-Fab串联多特异性结合蛋白及其制备和应用 |
| AR131494A1 (es) | 2022-12-23 | 2025-03-26 | Ablynx Nv | Vehículos de conjugación a base de proteína |
| WO2024151515A2 (en) | 2023-01-09 | 2024-07-18 | Odyssey Therapeutics, Inc. | Anti-tnfr2 antigen-binding proteins and uses thereof |
| CN120530125A (zh) * | 2023-01-18 | 2025-08-22 | 北京质肽生物医药科技有限公司 | 融合多肽的液体药物组合物及其使用方法 |
| US20240368250A1 (en) * | 2023-02-17 | 2024-11-07 | Ablynx N.V. | Polypeptides binding to the neonatal fc receptor |
| TW202444757A (zh) | 2023-03-14 | 2024-11-16 | 美商奧迪希治療公司 | 抗cd25抗原結合蛋白及其用途 |
| TW202446782A (zh) | 2023-04-11 | 2024-12-01 | 美商威特拉公司 | 愛帕琳受體促效劑及其用途 |
| WO2024231348A1 (en) | 2023-05-11 | 2024-11-14 | Vib Vzw | Slc4a4/nbce1 inhibitors |
| TW202448951A (zh) | 2023-05-17 | 2024-12-16 | 美商奧迪希治療公司 | 經修飾之單域抗體 |
| WO2024261235A1 (en) | 2023-06-22 | 2024-12-26 | Ablynx Nv | Chimeric proteins for modulating cytokine receptor activity |
| AR133108A1 (es) | 2023-06-29 | 2025-08-27 | Odyssey Therapeutics Inc | Proteínas de unión a antígeno anti-trailr2 y sus usos |
| TW202517676A (zh) | 2023-07-05 | 2025-05-01 | 比利時商艾伯霖克斯公司 | 用於治療ＩｇＧ相關疾病及病症之改良ＦｃＲｎ拮抗劑 |
| WO2025051767A1 (en) | 2023-09-04 | 2025-03-13 | Sanofi | Polypeptides for use in the treatment of glypican-3-expressing tumours |
| WO2025061919A1 (en) | 2023-09-22 | 2025-03-27 | Ablynx Nv | Bi- and multivalent albumin binders |
| WO2025080751A2 (en) | 2023-10-13 | 2025-04-17 | Odyssey Therapeutics, Inc. | Anti-cdh17 antigen-binding proteins and uses thereof |
| US20250152704A1 (en) | 2023-10-16 | 2025-05-15 | Paragon Therapeutics, Inc. | Fcrn antagonists with improved half-life and methods of use |
| WO2025099632A1 (en) | 2023-11-08 | 2025-05-15 | Sanofi | Cd25 based lysosomal degrader and uses thereof |
| WO2025106915A1 (en) | 2023-11-17 | 2025-05-22 | Sail Biomedicines, Inc. | Circular polyribonucleotides encoding glucagon-like peptide 1 (glp-1) and uses thereof |
| WO2025114529A1 (en) | 2023-12-01 | 2025-06-05 | Ablynx Nv | Multispecific antibodies recognising human serum albumin, tcr and a tumor antigen recognising moiety |
| WO2025133166A1 (en) | 2023-12-22 | 2025-06-26 | Ablynx Nv | Protein-based carriers for site-specific amine conjugation |
| WO2025133253A2 (en) | 2023-12-22 | 2025-06-26 | Ablynx Nv | Protein-based conjugation carriers for intranuclear delivery |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5608039A (en) | 1990-10-12 | 1997-03-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Single chain B3 antibody fusion proteins and their uses |
| ATE452207T1 (de) | 1992-08-21 | 2010-01-15 | Univ Bruxelles | Immunoglobuline ohne leichte ketten |
| EP0698097B1 (en) | 1993-04-29 | 2001-08-16 | Unilever N.V. | Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| DK1027439T3 (da) | 1997-10-27 | 2010-05-10 | Bac Ip Bv | Multivalente antigenbindende proteiner |
| IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
| US9321832B2 (en) * | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| FR2846667B1 (fr) | 2002-11-06 | 2004-12-31 | Pasteur Institut | Fragments variables d'anticorps de camelides a chaine unique diriges contre le peptide beta-amyloide 1-42 et leurs applications pour le diagnostic et le traitement des maladies neuroagregatives |
| EP2336179A1 (en) | 2002-11-08 | 2011-06-22 | Ablynx N.V. | Stabilized single domain antibodies |
| US9028816B2 (en) | 2003-01-10 | 2015-05-12 | Ablynx N.V. | Polypeptides and polypeptide constructs comprising single domain antibodies directed against von Willebrand factor |
| BRPI0513666A (pt) * | 2004-08-05 | 2008-05-13 | Genentech Inc | anticorpos, anticorpos anti c-met humanizados, método de inibição de proliferação celular de c-met ativado, método de modulação de uma doença associada com descontrole de sinalização de hgf/c-met, método para o tratamento de um sujeito com cáncer, método para o tratamento de um distúrbio proliferativo, ácido nucléico, célula hospedeira e composição |
| PT2949668T (pt) | 2005-05-18 | 2019-10-24 | Ablynx Nv | Nanobodies tm melhorados contra fator-alfa de necrose tumoral. |
| WO2006129843A2 (en) | 2005-05-31 | 2006-12-07 | Canon Kabushiki Kaisha | Bispecific capturing molecule |
| WO2006129828A2 (en) | 2005-05-31 | 2006-12-07 | Canon Kabushiki Kaisha | Target substance capturing molecule |
| CA2640066A1 (en) | 2006-01-24 | 2007-08-02 | Roland Beckmann | Fusion proteins that contain natural junctions |
| KR20080113218A (ko) * | 2006-03-30 | 2008-12-29 | 노파르티스 아게 | ｃ―Ｍｅｔ의 항체에 대한 사용 방법 및 조성물 |
| US7741273B2 (en) | 2006-04-13 | 2010-06-22 | Warsaw Orthopedic, Inc. | Drug depot implant designs |
| KR20090039739A (ko) | 2006-08-03 | 2009-04-22 | 아스트라제네카 아베 | αＶβ６에 대해 작용하는 항체 및 그의 용도 |
| CA2666599A1 (en) | 2006-08-18 | 2008-02-21 | Ablynx N.V. | Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling |
| EP2069402A2 (en) | 2006-09-08 | 2009-06-17 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
| CN101528767A (zh) * | 2006-10-11 | 2009-09-09 | 埃博灵克斯股份有限公司 | 以基本不依赖pH的方式结合血清蛋白的氨基酸序列、包括其的化合物、及其用途 |
| GB0706793D0 (en) | 2007-04-05 | 2007-05-16 | Evotec Ag | Compounds |
| NZ581097A (en) | 2007-05-24 | 2012-03-30 | Ablynx Nv | Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders |
| EP2014681A1 (en) | 2007-07-12 | 2009-01-14 | Pierre Fabre Medicament | Novel antibodies inhibiting c-met dimerization, and uses thereof |
| US8940298B2 (en) | 2007-09-04 | 2015-01-27 | The Regents Of The University Of California | High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection |
| AU2008304574A1 (en) | 2007-09-24 | 2009-04-02 | Vanderbilt University | Monoclonal antibodies to respiratory syncytial virus and uses thereof |
| AU2008328784B2 (en) | 2007-11-27 | 2014-03-27 | Ablynx N.V. | Immunoglobulin constructs |
| BRPI0907648B1 (pt) | 2008-01-29 | 2022-01-11 | Institute Of Molecular Biology And Genetics National Academy Of Science Of Ukraine | Anticorpo isolado humanizado, usos de um anticorpo, métodos para preparar um anticorpo, para gerar anticorpos imunorreativos com slc34a2 e para triar ou identificar agentes ou compostos que modulam slc34a2, composições, ácido nucleico isolado, e, microorganismo hospedeiro |
| RU2010151725A (ru) | 2008-05-16 | 2012-06-27 | Аблинкс Нв (Be) | Аминокислотные последовательности, направленные против cхcr4 и других gpcr, и соединения, включаюшие их |
| AU2009254501B2 (en) | 2008-06-05 | 2014-07-31 | Ablynx N.V. | Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases |
| EP2143735A1 (en) | 2008-07-10 | 2010-01-13 | Institut Pasteur | Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins |
| US20110200525A1 (en) | 2008-10-09 | 2011-08-18 | Patz Jr Edward F | Vhh antibody fragments for use in the detection and treatment of cancer |
| JP6113404B2 (ja) | 2008-10-29 | 2017-04-12 | アブリンクス エン．ヴェー． | 単一ドメイン抗原結合分子の精製方法 |
| MA33221B1 (fr) * | 2009-03-27 | 2012-04-02 | Glaxo Group Ltd | Fusions de médicament et conjugués afférents |
| EP2507262A1 (en) | 2009-11-30 | 2012-10-10 | Ablynx N.V. | Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections |
| UY33115A (es) | 2009-12-18 | 2011-07-29 | Sanofi Aventis | NUEVOS ANTICUERPOS ANTAGONISTAS Y SUS FRAGMENTOS Fab CONTRA GPVI Y SUS USOS |
| AP2012006359A0 (en) | 2010-03-03 | 2012-08-31 | Boehringer Ingelheim Int | Biparatopic abeta binding polypeptides |
| CA3157780A1 (en) | 2010-03-10 | 2011-09-15 | Genmab A/S | Monoclonal antibodies against c-met |
| EP2621953B1 (en) * | 2010-09-30 | 2017-04-05 | Ablynx N.V. | Biological materials related to c-met |
| US11644471B2 (en) | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| PH12022550312A1 (en) | 2011-06-23 | 2023-01-23 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| US20150344568A1 (en) | 2011-06-23 | 2015-12-03 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| EP4218933A1 (en) * | 2011-06-23 | 2023-08-02 | Ablynx NV | Serum albumin binding proteins |
| US10808040B2 (en) | 2011-08-17 | 2020-10-20 | Glaxo Group Limited | Modified proteins and peptides |
| US9346884B2 (en) | 2011-09-30 | 2016-05-24 | Ablynx N.V. | Biological materials related to c-Met |
-
2012
- 2012-06-14 EP EP23159592.7A patent/EP4218933A1/en active Pending
- 2012-06-14 CA CA2839779A patent/CA2839779C/en active Active
- 2012-06-14 EP EP12727658.2A patent/EP2723771B1/en active Active
- 2012-06-14 CN CN201280030647.8A patent/CN103619878B/zh active Active
- 2012-06-14 CN CN201610392570.9A patent/CN106046168A/zh active Pending
- 2012-06-14 DK DK12727658T patent/DK2723771T3/da active
- 2012-06-14 SI SI201231696T patent/SI2723771T1/sl unknown
- 2012-06-14 EP EP18205150.8A patent/EP3466972A1/en active Pending
- 2012-06-14 AU AU2012271974A patent/AU2012271974B2/en active Active
- 2012-06-14 HR HRP20192160TT patent/HRP20192160T1/hr unknown
- 2012-06-14 PT PT127276582T patent/PT2723771T/pt unknown
- 2012-06-14 US US14/128,719 patent/US9573992B2/en active Active
- 2012-06-14 ES ES12727658T patent/ES2759936T3/es active Active
- 2012-06-14 PL PL12727658T patent/PL2723771T3/pl unknown
- 2012-06-14 WO PCT/EP2012/061304 patent/WO2012175400A1/en active Application Filing
- 2012-06-14 HU HUE12727658A patent/HUE047238T2/hu unknown
- 2012-06-14 JP JP2014516279A patent/JP6324887B2/ja active Active
- 2012-06-14 LT LT12727658T patent/LT2723771T/lt unknown
- 2012-06-14 IN IN414CHN2014 patent/IN2014CN00414A/en unknown
- 2012-06-25 HR HRP20170535TT patent/HRP20170535T4/hr unknown
-
2017
- 2017-01-03 US US15/397,313 patent/US20170210789A1/en not_active Abandoned
-
2018
- 2018-04-11 JP JP2018076201A patent/JP6843090B2/ja active Active
-
2019
- 2019-12-10 CY CY20191101299T patent/CY1122691T1/el unknown
-
2021
- 2021-02-22 JP JP2021026177A patent/JP7304375B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2014520129A (ja) | 2014-08-21 |
| CN103619878A (zh) | 2014-03-05 |
| HRP20170535T1 (hr) | 2017-06-16 |
| US20140228546A1 (en) | 2014-08-14 |
| WO2012175400A1 (en) | 2012-12-27 |
| DK2723771T3 (da) | 2019-12-02 |
| JP2021088585A (ja) | 2021-06-10 |
| LT2723771T (lt) | 2019-12-10 |
| PL2723771T3 (pl) | 2020-04-30 |
| SI2723771T1 (sl) | 2019-12-31 |
| AU2012271974B2 (en) | 2017-01-12 |
| CY1122691T1 (el) | 2021-03-12 |
| IN2014CN00414A (en:Method) | 2015-04-03 |
| JP6843090B2 (ja) | 2021-03-17 |
| JP2018127478A (ja) | 2018-08-16 |
| EP3466972A1 (en) | 2019-04-10 |
| US20170210789A1 (en) | 2017-07-27 |
| HUE047238T2 (hu) | 2020-04-28 |
| EP2723771B1 (en) | 2019-09-11 |
| CN106046168A (zh) | 2016-10-26 |
| EP2723771A1 (en) | 2014-04-30 |
| CA2839779A1 (en) | 2012-12-27 |
| CA2839779C (en) | 2020-10-06 |
| PT2723771T (pt) | 2019-12-11 |
| US9573992B2 (en) | 2017-02-21 |
| CN103619878B (zh) | 2016-10-26 |
| EP4218933A1 (en) | 2023-08-02 |
| HRP20192160T1 (hr) | 2020-02-21 |
| AU2012271974A1 (en) | 2013-12-12 |
| JP6324887B2 (ja) | 2018-05-16 |
| JP7304375B2 (ja) | 2023-07-06 |
| HRP20170535T4 (hr) | 2022-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2759936T3 (es) | Proteínas de unión a albúmina sérica | |
| US20230060574A1 (en) | Serum albumin binders | |
| US20230050615A1 (en) | Improved serum albumin binding immunoglobulin single variable domains | |
| EP3571224B1 (en) | Improved serum albumin binders | |
| EP1888641B1 (en) | Serum albumin binding proteins | |
| CN107922495A (zh) | 结合egfrviii和cd3的双特异性抗体构建体 | |
| EP3808771A1 (en) | Gipr antibody and glp-1 fusion protein thereof, and pharmaceutical composition and application thereof | |
| JP2025131869A (ja) | 改善された血清アルブミン結合性免疫グロブリン単一可変ドメイン | |
| WO2023219120A1 (ja) | 抗ｃｄ３７－抗ｃｄ３二重特異性抗体 | |
| TW202421663A (zh) | Gipr抗體及其與fgf21的融合蛋白，以及其藥物組合物和應用 | |
| HK40018516A (en) | Improved serum albumin binders | |
| HK40018516B (en) | Improved serum albumin binders | |
| HK40017968A (en) | Improved serum albumin binders | |
| HK40017968B (en) | Improved serum albumin binders |